BioSpace News Archive

RaySearch has received 510 clearance from the FDA in the USA for version 8B of the treatment planning system RayStation®.

Total net revenues of SEK 201.2 million (199.7), up 0.8 percent and 19.1 percent when excluding ex-US milestone payment of SEK 30.8 million in Q2 2018

BTG plc, the global healthcare company, highlighted the first publication of National Comprehensive Cancer Network pediatric acute lymphoblastic leukemia guidelines including consideration of Voraxaze®.

Sage Therapeutics, a biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced it will host a live webcast on Tuesday, August 6, 2019 at 8:00 a.m. EDT to report its second quarter 2019 financial results and discuss recent business updates.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will release second-quarter 2019 financial results before the market opens on Thursday, July 25, 2019, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

A new report from WebMD finds that while grief is nearly universal, most people feel rushed to “get over it,” and find social media posts about their loss among the least helpful responses from others during the grieving process.

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced that it has entered into a collaboration agreement with Paragon Gene Therapy, a unit of Catalent Biologics, for the development of a dedicated manufacturing suite at their facility near Baltimore, Maryland.

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a webinar that will present the latest in vitro research methods and International Transporter Consortium (ITC) guidance for assessing bile salt export pump (BSEP) inhibition to reduce and manage the risk of drug-induced liver injury (DILI) during drug development.

ObjectiveGI is delivering provider partners and their patients participating in research a new, all-inclusive platform of clinical research data management.

Circassia Pharmaceuticals, Inc. (“Circassia” or “the Company”), a specialty pharmaceutical company focused on respiratory disease, today announced that it has been awarded a group purchasing agreement for Pulmonary Function and Metabolic Analyzers with Premier.